On August 5, 2025, REGENXBIO Inc. amended its collaboration agreement with AbbVie to modify the diabetic retinopathy program's development plan, with AbbVie investing milestones of up to $200 million for trials-related payments.
AI Assistant
REGENXBIO INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.